Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief: Adaptive, Arctic Vision, Artiva, Arvinas, Bio-Thera Solutions, Clearside Biomedical, Curebase, Curevac, Dyadic International, Finch, Futuregen, GC Labcell, Gracell, HDT, Insilico Medicine Hong Kong, Johnson & Johnson, Moderna, Nobelpharma, Novartis, Noxopharm, Nyrada, Orizuru, Probiogen, Quratis, RDIF, Sab, Sen-Jam, Skye, Sorrento, Sunshine, Takeda, Therapeutic Solutions International.

New hires and promotions in the biopharma industry in Asia-Pacific, including: Insilico Medicine Hong Kong, PYC Therapeutics.

Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific: Advaccine, Ascletis, Belief Biomed, Biohaven, Biontech, Cipla, Coherus, GC, Innocare, Inovio, Junshi, Merck Sharp & Dohme (Australia), Moderna, Novatek, Pfizer, Phasebio, Rigel, SFJ, Yisheng.

Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications: Atea, Athersys, Azurrx, Bavarian Nordic, Biontech, Daiichi Sankyo, Gigagen, I-Mab, Immvira, Innovation, Innovent, Lynk, Nrx, Opthea, Pfizer, Sinovac, Valneva.

Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific: Abl Bio, Akeso, Antengene, Arcturus, Canbridge, China Pharma Holdings, Cytodyn, Everest Medicines, Hummingbird, Iaso, Immvira, Panther, Regeneron, Shenzhen Kangtai Biological Products, Sino, Therapeutic Solutions International, Vaxart.

Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief: Abbvie, Academia Sinica, Allarity, Anpac Bio-Medical Science, Antengene, Athersys, Biodelivery Sciences International, Burning Rock, Celularity, China Grand Pharmaceutical and Healthcare Holdings, Dr. Reddy’s Laboratories, Enanta, Etherna Asia, Etherna Immunotherapies, GC, Glenmark, Healios, Impact, Imugene, Inmagene, Insilico Medicine Hong Kong, Ji Xing, Kissei, Kyowa Kirin, Mindrank, Mymd, Novartis, Novavax, Olix, Oyster Point, Pharmaxis, Roche, Sanotize Research and Development, Sorrento, Stemcyte, Synaffix, Takeda, Usynova, Westlake, Yuyu.

Biopharmas in Asia-Pacific raising money in public or private financings: Adagio, Appili.

Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications: Akston, Brii, Eli Lilly, Humanigen, Immutep, Incyte, Jacobio, Kiniksa, Lumosa, Novavax, Pharmaxis, RDIF, Stemedica Cell Technologies, Takeda, Telix, Vanda.